Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27184)	1/5/1999 10:41:00 AM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

the market is approving of LGND this a.m. any thoughts on whether its the Murphy/CNBC, II mentions of reaction to the warrant deal? Probably all of the above.

To: Henry Niman who wrote (27184)	1/5/1999 11:16:00 AM
From: Machaon	Respond to of 32384

<< Jim McCamant of the Medical Technology Stock Letter has a $30 price target on LGND >> Ahhhhhhh!? The sweet smell of positive hype. Thanks for the reference to the Online Investor's article about LGND. It was the most positive article I have read so far. I think that some of the frustrations of holding onto a somewhat dead investment, aka: LGND, are coming to a head. The only positive LGND shareholders have seen in 1998 was the bounce back up towards $12, for those that bought a bunch down there near the bottom. I am glad that LGND got $12 million without any further dilution. I don't think that this deal has negatively effected my LGNDW holdings. We need an FDA approval for ONTAK and Panretin Gel. Ligand needs cash to gear up for marketing their two new products, and for submitting new INDs and NDAs, the Seragen payoff for ONTAK approval, and further product acquisitions. The start of a Phase II Targretin trial for breast cancer, in the 4th quarter, will also require cash. If Ligand can get results anywhere close to the great preclinical results for Targretin, this could be a real blockbuster. If Ligand was a race car, they would be at the point where the tires have been put on the car, the engine is tuned and ready to go. Gentlemen, start your engines! <g> Regards, Bob ps: Warning, this note contains positive remarks about Ligand. I apologize to those that are offended by such remarks.

To: Henry Niman who wrote (27184)	1/5/1999 1:11:00 PM
From: Bryce Elkins	Respond to of 32384

TD - The bottom line of Henry's reference is nice: Ligand is a very well-funded niche biotechnology company, with two marketable products in Panretin and Ontak, and three more NDAs expected for 1999. The outlook for Ligand shares appears especially bright, since there is a strong likelihood the company will be profitability in 1999. Jim McCamant of the Medical Technology Stock Letter, believes Ligand shares are a buy under $16. He has a $30 price target on the stock, which was recently trading at $11.63. Ble